Microvascular AnginaNCT06070662
Non-invasive Diagnosis of Coronary Microvascular Disease: Pilot Study
An observational study of Microvascular Angina, run by University of Leicester at 1 site in United Kingdom.
Trial summary
40% of patients presenting with stable chest pain (angina) have no significant blockage of the main heart arteries. Identifying why these patients have symptoms will mean better treatment options can be developed. About 60% of these patients have evidence of coronary microvascular disease (CMD). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Microvascular Angina
- What is being tested?
- Coronary microvascular disease testing during coronary angiography, Cardiac magnetic resonance scan including exercise and Additional analysis of already acquired CT scan
- How many people
- 20 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 1 Nov 2023to Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients with suspected angina referred for invasive coronary angiography who are a current participants of the 'CMR versus CT-FFR in CAD' study.
Who may be able to join
- Current participant of the 'CMR versus CT-FFR in CAD' study
- Continue to meet the inclusion criteria for the main study:
- Patients aged ≥18 years
- Referred for invasive coronary angiography for investigation of chest pain
- Willing and able to give informed consent
- Willing and able (in the Investigators opinion) to comply with all study requirements.
Show all 14Show fewer
- Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study.
- Able to understand written English
- Able to perform exercise in the MRI scanner
- Study arm:
- No evidence of obstructive or non-obstructive CAD on research CTCA
- Myocardial perfusion defect detected on adenosine stress CMR indicative of CMD
- Control arm:
- Evidence of multivessel CAD on research CTCA
Who cannot join
- Meet the exclusion criteria for the main study:
- Recent acute coronary syndrome (< 6 months)
- Severe claustrophobia
- Absolute contraindications to CMR - those with MR conditional or safe devices will be included
- Second-/third-degree atrioventricular block
- Severe chronic obstructive pulmonary disease
Show all 12Show fewer
- Moderate-severe asthma
- Estimated glomerular filtration rate <30 ml/min/1.73m2
- Women who are pregnant, breast-feeding or of child-bearing potential (premenopausal women)
- Contraindication to iodinated contrast
- Participants who have participated in a research study involving an investigational product in the past 12 weeks
- Patients unable to understand written English
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Sarah L Ayton, MBBS contact
United Kingdom1 site, 1 recruiting
- Recruiting
Glenfield Hospital, University Hospitals of Leicester
Leicester, Leicestershire
Ranjit Arnold, jra14@leicester.ac.uk
About this study
Official title: Non-invasive Diagnosis of Coronary Microvascular Disease Using Novel CMR and CT Techniques: a Pilot Study
- 40% of patients presenting with stable chest pain (angina) have no significant blockage of the main heart arteries. Identifying why these patients have symptoms will mean better treatment options can be developed.
- About 60% of these patients have evidence of coronary microvascular disease (CMD). In this condition there is a problem with the heart's microvessels (very small blood vessels that branch from the main heart arteries). Due to problems with these vessels there is a mismatch between the blood supply to the heart and its oxygen consumption, causing chest pain and this can also lead to major heart events.
- At present, to diagnose this condition, specialised techniques during an invasive test, called a coronary angiogram, are required. As this is an invasive test, it can be lead to complications and cause discomfort.
- Non-invasive ways of diagnosing CMD are required to improve the diagnosis and management of this condition.
- This study aims to provide initial data on whether novel imaging techniques using CT and MRI scans, which are much less invasive, could identify CMD.
- To do this, patients with suspected angina referred for angiography and who are already participants in the main research study 'CMR versus CT-FFR in CAD' study will be recruited.
- These will be patients with suspected CMD and also those with blockage of the main heart arteries (triple vessel disease) to compare against.
- Participants in this pilot study will have additional tests used to diagnose CMD during their invasive angiography procedure. Participants will then have an MRI scan involving novel techniques and exercise MRI, where individuals exercise use a cycle or stepping machine during the MRI scan. Further analysis will also be undertaken of CT images acquired as part of the main study.
- These tests will be compared against invasive test results to see which show potential in being able to diagnose CMD.
Read the detailed description
- Coronary artery disease (CAD) is the leading cause of morbidity and mortality in the United Kingdom. Approximately 40% of patients presenting with angina, however, have no evidence of significant obstructive CAD.
- About 60% of these patients have evidence of coronary microvascular disease (CMD), where there is dysfunction of the coronary microvessels leading to a mismatch between the blood supply to the myocardium and oxygen consumption. This may be due to a number of structural and functional changes including vascular remodelling, perivascular fibrosis, endothelial dysfunction and vascular smooth muscle dysfunction. Although previously thought of as a benign entity, recent studies suggest that CMD is associated with major adverse events.
- Symptoms caused by CMD and obstructive CAD cannot be distinguished sufficiently to guide diagnosis and management plans and conventional cardiac risk factors are poor discriminators of the two conditions, therefore clinicians are reliant on further investigations to diagnose CMD.
- Growing evidence supports invasive coronary physiological testing for this and methods to measure coronary vascular function during angiography have been developed. Once significant epicardial CAD has been excluded, CMD can be identified by impaired coronary flow reserve (CFR) and the index of microvascular resistance (IMR).
- Despite the ability of invasive testing to detect CMD, these methods come with attendant risks, as well as cost implications. Additionally, there is limited expertise and uptake amongst interventional cardiologists in intracoronary physiological assessment, limiting its widespread use. Hence, non-invasive surrogates are required to improve diagnosis and management of CMD. However, currently available non-invasive tests, including exercise ECG, stress echocardiography and nuclear imaging, lack the sensitivity and specificity to diagnose CMD.
- Microvascular volume analysed using novel imaging methods may provide the diagnostic accuracy required for the non-invasive identification of CMD. In CMD, patients may exhibit reduced microvascular volume, in contrast to epicardial disease where there is microvascular expansion and therefore these methods may be able to differentiate between the two disease processes. A number of methods have been proposed for assessment of microvascular volume using computed tomography (CT) and CMR. These methods include coronary luminal volume to myocardial mass (V/M) ratio using computational CT analysis, as well as CMR methods such as T1 mapping and Blood oxygen level-dependent CMR. Furthermore, compared to using pharmacological stress, exercise CMR could provide superior diagnostic ability to identify CMD, as it allows assessment during more 'physiological' stress.
- This study aims to provide pilot data on whether these novel CT and MRI and the use of physiological stress (exercise CMR) could identify CMD in patients presenting with angina. It aims to identify which of the proposed imaging methods could prove to be clinically useful for non-invasive identification of CMD, providing justification for a larger-scale diagnostic accuracy study.
- This is a prospective, single centre pilot study which will recruit individuals with angina referred for angiography who are participants in the research study 'CMR versus CT-FFR in CAD'.
- This pilot study will recruit both patients with suspected CMD and controls with multi-vessel CAD to compare against.
- Participants will be consented to have additional invasive testing at angiography for CMD. Those with confirmed CMD at angiography and all control participants will then have an MRI scan compromising of advanced MRI techniques for assessment of microvascular volume at rest and physiological stress (exercise). In addition, previously acquired CT images from the main research study will be transferred to Heartflow for computation of coronary blood volume.
- This will allow assessment of whether the novel imaging modalities proposed could be clinically useful for non-invasive identification of CMD and distinction from epicardial disease to inform larger future studies of these techniques.
- Conditions
- Microvascular Angina
- Being tested
- Coronary microvascular disease testing during coronary angiography, Cardiac magnetic resonance scan including exercise, Additional analysis of already acquired CT scan
- Keywords
- Coronary microvascular disease, Angina, Non-invasive testing
- Medical subject headings
- Microvascular Angina, Angina Pectoris
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Coronary microvascular disease testing during coronary angiographyDiagnostic test
During invasive coronary angiography, in addition to coronary angiography performed as per routine clinical care, participants will have angiographic testing for coronary microvascular disease using routine clinical procedures. This will consist of fractional flow reserve (FFR), coronary flow reserve, index of microvascular resistance and vasospasm provocation testing with acetylcholine (Ach).
Cardiac magnetic resonance scan including exerciseDiagnostic test
Participants will undergo a cardiac magnetic resonance scan compromising 1) T1 mapping, 2) oxygenation-sensitive MRI and 3) perfusion imaging. All will be obtained at rest and during exercise using a step ergometer.
Additional analysis of already acquired CT scanDiagnostic test
Previously acquired CTCA images from the main research study will be transferred to Heartflow for computation of coronary blood volume.
| Study group | Role | What they receive |
|---|---|---|
| Suspected coronary microvascular disease confirmed at angiography (expected n=8) | Individuals with suspected coronary microvascular disease based on CT and MRI scans completed as part of the main research study. Those with confirmed coronary microvascular disease will complete an MRI scan as part of this pilot study and their CT scan will undergo additional analysis. Receives: Diagnostic Test: Coronary microvascular disease testing during coronary angiography; Diagnostic Test: Cardiac magnetic resonance scan including exercise; Diagnostic Test: Additional analysis of already acquired CT scan | |
| Suspected coronary microvascular disease not confirmed at angiography (expected n=4) | Individuals with suspected coronary microvascular disease based on CT and MRI scans completed as part of the main research study. If this is not confirmed coronary microvascular disease they will not undergo any further investigations as part of this research study. Receives: Diagnostic Test: Coronary microvascular disease testing during coronary angiography | |
| Multivessel coronary artery disease (n=12) | Individuals with multivessel coronary artery disease, diagnosed based on CT and MRI scans completed as part of the main research study and confirmed at angiography. Receives: Diagnostic Test: Coronary microvascular disease testing during coronary angiography; Diagnostic Test: Cardiac magnetic resonance scan including exercise; Diagnostic Test: Additional analysis of already acquired CT scan |
What is being measured
The primary outcome is the main question the study is designed to answer.
The ability of coronary luminal volume to myocardial mass (V/M) ratio measured using CT to identify the presence of CMD demonstrated by invasive coronary physiological assessment in patients with angina.
Measured: At time of imaging scan
The ability of T1 mapping at rest and exercise to identify the presence of CMD demonstrated by invasive coronary physiological assessment in patients with angina.
Measured: At time of imaging scan
The ability of Blood oxygen level-dependent CMR (BOLD-CMR) at rest and exercise at rest and exercise to identify the presence of CMD demonstrated by invasive coronary physiological assessment in patients with angina.
Measured: At time of imaging scan
The ability of CMR perfusion imaging at rest and exercise to identify the presence of CMD demonstrated by invasive coronary physiological assessment in patients with angina.
Measured: At time of imaging scan
The ability of myocardial blood volume as measured by CMR first-pass perfusion imaging at rest and during exercise to identify the presence of CMD demonstrated by invasive coronary physiological assessment in patients with angina.
Measured: At time of imaging scan
Secondary outcomes (2)
T1 mapping at rest and adenosine-induced hyperaemia to identify the presence of CMD demonstrated by invasive coronary physiological assessment in patients with angina.
Measured: At time of imaging scan
CMR perfusion imaging at rest and adenosine-induced hyperaemia to identify the presence of CMD demonstrated by invasive coronary physiological assessment in patients with angina.
Measured: At time of imaging scan
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Oct 2023
- Study start1 Nov 2023
- Primary completionDec 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Microvascular AnginaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Leicester
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Ranjit Arnold, Principal investigator, University of Leicester
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06070662
- Sponsor's protocol ID
- 0844
- Status last verified
- Apr 2026
- First submitted
- 25 Mar 2022
- Last updated
- 30 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 30 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Non-invasive Diagnosis of Coronary Microvascular Disease Using Novel CMR and CT Techniques: a Pilot Study
- ClinicalTrials.gov ID
- NCT06070662
- Acronym / sponsor ID
- 0844
- Conditions
- Microvascular Angina
- Keywords
- Coronary microvascular disease, Angina, Non-invasive testing
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- University of LeicesterUniversity, hospital or other
- Study start
- 1 Nov 2023 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 6 Oct 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
- 40% of patients presenting with stable chest pain (angina) have no significant blockage of the main heart arteries. Identifying why these patients have symptoms will mean better treatment options can be developed.
- About 60% of these patients have evidence of coronary microvascular disease (CMD). In this condition there is a problem with the heart's microvessels (very small blood vessels that branch from the main heart arteries). Due to problems with these vessels there is a mismatch between the blood supply to the heart and its oxygen consumption, causing chest pain and this can also lead to major heart events.
- At present, to diagnose this condition, specialised techniques during an invasive test, called a coronary angiogram, are required. As this is an invasive test, it can be lead to complications and cause discomfort.
- Non-invasive ways of diagnosing CMD are required to improve the diagnosis and management of this condition.
- This study aims to provide initial data on whether novel imaging techniques using CT and MRI scans, which are much less invasive, could identify CMD.
- To do this, patients with suspected angina referred for angiography and who are already participants in the main research study 'CMR versus CT-FFR in CAD' study will be recruited.
- These will be patients with suspected CMD and also those with blockage of the main heart arteries (triple vessel disease) to compare against.
- Participants in this pilot study will have additional tests used to diagnose CMD during their invasive angiography procedure. Participants will then have an MRI scan involving novel techniques and exercise MRI, where individuals exercise use a cycle or stepping machine during the MRI scan. Further analysis will also be undertaken of CT images acquired as part of the main study.
- These tests will be compared against invasive test results to see which show potential in being able to diagnose CMD.
Detailed description
- Coronary artery disease (CAD) is the leading cause of morbidity and mortality in the United Kingdom. Approximately 40% of patients presenting with angina, however, have no evidence of significant obstructive CAD.
- About 60% of these patients have evidence of coronary microvascular disease (CMD), where there is dysfunction of the coronary microvessels leading to a mismatch between the blood supply to the myocardium and oxygen consumption. This may be due to a number of structural and functional changes including vascular remodelling, perivascular fibrosis, endothelial dysfunction and vascular smooth muscle dysfunction. Although previously thought of as a benign entity, recent studies suggest that CMD is associated with major adverse events.
- Symptoms caused by CMD and obstructive CAD cannot be distinguished sufficiently to guide diagnosis and management plans and conventional cardiac risk factors are poor discriminators of the two conditions, therefore clinicians are reliant on further investigations to diagnose CMD.
- Growing evidence supports invasive coronary physiological testing for this and methods to measure coronary vascular function during angiography have been developed. Once significant epicardial CAD has been excluded, CMD can be identified by impaired coronary flow reserve (CFR) and the index of microvascular resistance (IMR).
- Despite the ability of invasive testing to detect CMD, these methods come with attendant risks, as well as cost implications. Additionally, there is limited expertise and uptake amongst interventional cardiologists in intracoronary physiological assessment, limiting its widespread use. Hence, non-invasive surrogates are required to improve diagnosis and management of CMD. However, currently available non-invasive tests, including exercise ECG, stress echocardiography and nuclear imaging, lack the sensitivity and specificity to diagnose CMD.
- Microvascular volume analysed using novel imaging methods may provide the diagnostic accuracy required for the non-invasive identification of CMD. In CMD, patients may exhibit reduced microvascular volume, in contrast to epicardial disease where there is microvascular expansion and therefore these methods may be able to differentiate between the two disease processes. A number of methods have been proposed for assessment of microvascular volume using computed tomography (CT) and CMR. These methods include coronary luminal volume to myocardial mass (V/M) ratio using computational CT analysis, as well as CMR methods such as T1 mapping and Blood oxygen level-dependent CMR. Furthermore, compared to using pharmacological stress, exercise CMR could provide superior diagnostic ability to identify CMD, as it allows assessment during more 'physiological' stress.
- This study aims to provide pilot data on whether these novel CT and MRI and the use of physiological stress (exercise CMR) could identify CMD in patients presenting with angina. It aims to identify which of the proposed imaging methods could prove to be clinically useful for non-invasive identification of CMD, providing justification for a larger-scale diagnostic accuracy study.
- This is a prospective, single centre pilot study which will recruit individuals with angina referred for angiography who are participants in the research study 'CMR versus CT-FFR in CAD'.
- This pilot study will recruit both patients with suspected CMD and controls with multi-vessel CAD to compare against.
- Participants will be consented to have additional invasive testing at angiography for CMD. Those with confirmed CMD at angiography and all control participants will then have an MRI scan compromising of advanced MRI techniques for assessment of microvascular volume at rest and physiological stress (exercise). In addition, previously acquired CT images from the main research study will be transferred to Heartflow for computation of coronary blood volume.
- This will allow assessment of whether the novel imaging modalities proposed could be clinically useful for non-invasive identification of CMD and distinction from epicardial disease to inform larger future studies of these techniques.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Suspected coronary microvascular disease confirmed at angiography (expected n=8) | – | Diagnostic Test: Coronary microvascular disease testing during coronary angiography, Diagnostic Test: Cardiac magnetic resonance scan including exercise, Diagnostic Test: Additional analysis of already acquired CT scanIndividuals with suspected coronary microvascular disease based on CT and MRI scans completed as part of the main research study. Those with confirmed coronary microvascular disease will complete an MRI scan as part of this pilot study and their CT scan will undergo additional analysis. |
| Suspected coronary microvascular disease not confirmed at angiography (expected n=4) | – | Diagnostic Test: Coronary microvascular disease testing during coronary angiographyIndividuals with suspected coronary microvascular disease based on CT and MRI scans completed as part of the main research study. If this is not confirmed coronary microvascular disease they will not undergo any further investigations as part of this research study. |
| Multivessel coronary artery disease (n=12) | – | Diagnostic Test: Coronary microvascular disease testing during coronary angiography, Diagnostic Test: Cardiac magnetic resonance scan including exercise, Diagnostic Test: Additional analysis of already acquired CT scanIndividuals with multivessel coronary artery disease, diagnosed based on CT and MRI scans completed as part of the main research study and confirmed at angiography. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients with suspected angina referred for invasive coronary angiography who are a current participants of the 'CMR versus CT-FFR in CAD' study.
Key inclusion criteria (14 listed)
- Current participant of the 'CMR versus CT-FFR in CAD' study
- Continue to meet the inclusion criteria for the main study:
- Patients aged ≥18 years
- Referred for invasive coronary angiography for investigation of chest pain
- Willing and able to give informed consent
Key exclusion criteria (12 listed)
- Meet the exclusion criteria for the main study:
- Recent acute coronary syndrome (< 6 months)
- Severe claustrophobia
- Absolute contraindications to CMR - those with MR conditional or safe devices will be included
- Second-/third-degree atrioventricular block
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Coronary microvascular disease testing during coronary angiographyDuring invasive coronary angiography, in addition to coronary angiography performed as per routine clinical care, participants will have angiographic testing for coronary microvascular disease using routine clinical procedures. This will consist of fractional flow reserve (FFR), coronary flow reserve, index of microvascular resistance and vasospasm provocation testing with acetylcholine (Ach). | Diagnostic test | Multivessel coronary artery disease (n=12), Suspected coronary microvascular disease confirmed at angiography (expected n=8), Suspected coronary microvascular disease not confirmed at angiography (expected n=4) |
| Cardiac magnetic resonance scan including exerciseParticipants will undergo a cardiac magnetic resonance scan compromising 1) T1 mapping, 2) oxygenation-sensitive MRI and 3) perfusion imaging. All will be obtained at rest and during exercise using a step ergometer. | Diagnostic test | Multivessel coronary artery disease (n=12), Suspected coronary microvascular disease confirmed at angiography (expected n=8) |
| Additional analysis of already acquired CT scanPreviously acquired CTCA images from the main research study will be transferred to Heartflow for computation of coronary blood volume. | Diagnostic test | Multivessel coronary artery disease (n=12), Suspected coronary microvascular disease confirmed at angiography (expected n=8) |
Primary outcome
The ability of coronary luminal volume to myocardial mass (V/M) ratio measured using CT to identify the presence of CMD demonstrated by invasive coronary physiological assessment in patients with angina.
Time frame: At time of imaging scan
The ability of T1 mapping at rest and exercise to identify the presence of CMD demonstrated by invasive coronary physiological assessment in patients with angina.
Time frame: At time of imaging scan
The ability of Blood oxygen level-dependent CMR (BOLD-CMR) at rest and exercise at rest and exercise to identify the presence of CMD demonstrated by invasive coronary physiological assessment in patients with angina.
Time frame: At time of imaging scan
The ability of CMR perfusion imaging at rest and exercise to identify the presence of CMD demonstrated by invasive coronary physiological assessment in patients with angina.
Time frame: At time of imaging scan
The ability of myocardial blood volume as measured by CMR first-pass perfusion imaging at rest and during exercise to identify the presence of CMD demonstrated by invasive coronary physiological assessment in patients with angina.
Time frame: At time of imaging scan
2 secondary outcomes
T1 mapping at rest and adenosine-induced hyperaemia to identify the presence of CMD demonstrated by invasive coronary physiological assessment in patients with angina.
Time frame: At time of imaging scan
CMR perfusion imaging at rest and adenosine-induced hyperaemia to identify the presence of CMD demonstrated by invasive coronary physiological assessment in patients with angina.
Time frame: At time of imaging scan
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Apr 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Microvascular Angina
Active, not recruitingObservational study
The DISCOVER INOCA Prospective Multi-center Registry
Ischemia and No Obstructive Coronary Artery Disease, Coronary Microvascular Dysfunction
RecruitingObservational study
The Value of Measuring Retinal Vascular Density by Optical Coherence Tomography-Angiography (OCT-A) in Patients With Microvascular Angina Confirmed by Myocardial Microcirculatory Resistance Index (MRI).
Microvascular Angina
Not yet recruitingPhase 4
Coronary MicrovAscular Diseases Intervention With Compound Danshen Dropping Pills
Coronary Microvascular Disease
Active, not recruitingPhase 2
Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations
NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations
Not yet recruiting
Coronary Sinus Reducer Objective Impact on SymptoMs, Ischaemia and miCrovascular Resistance in Non-obstructive Hypertrophic CardioMyopathy
Hypertrophic Cardiomyopathy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Sarah L Ayton, MBBS contact
Ranjit Arnold principal investigator
University of Leicester
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Microvascular Angina, run by University of Leicester at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 30 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ranjit Arnold (+44116 258 3038, jra14@leicester.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The ability of coronary luminal volume to myocardial mass (V/M) ratio measured using CT to identify the presence of CMD demonstrated by invasive coronary physiological assessment in patients with angina. (time frame: At time of imaging scan). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Apr 2026.